{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:37:18Z","timestamp":1793497038031,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ajog.2021.05.031","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T23:13:40Z","timestamp":1622243620000},"page":"513.e1-513.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-9575","authenticated-orcid":false,"given":"Benjamin B.","family":"Albright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan R.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley A.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Sonalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.05.031_bib1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMcp0900696","article-title":"Clinical practice. Molar pregnancy","volume":"360","author":"Berkowitz","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.05.031_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0889-8588(05)70162-3","article-title":"Recent advances in gestational trophoblastic disease","volume":"13","author":"Newlands","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ajog.2021.05.031_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/AOG.0000000000003566","article-title":"Gestational trophoblastic neoplasia After human chorionic gonadotropin normalization following molar pregnancy: a systematic review and meta-analysis","volume":"135","author":"Albright","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"Suppl1","key":"10.1016\/j.ajog.2021.05.031_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0020-7292(03)90120-2","article-title":"Gestational trophoblastic neoplasia, FIGO 2000 staging and classification","volume":"83","author":"Ngan","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2021.05.031_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2016.08.330","article-title":"15years of progress in gestational trophoblastic disease: scoring, standardization, and salvage","volume":"144","author":"Brown","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib6","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0002-9378(96)70229-6","article-title":"Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy","volume":"174","author":"Roberts","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.031_bib7","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1067\/mob.2000.108077","article-title":"Methotrexate infusion in low-risk gestational trophoblastic disease","volume":"183","author":"Wong","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.031_bib8","first-page":"199","article-title":"Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO Stages II-IV: risk factor score > or\u00a0= 7","volume":"55","author":"Lurain","year":"2010","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.ajog.2021.05.031_bib9","first-page":"7","article-title":"Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. Experience, 1995-2010","volume":"59","author":"Agarwal","year":"2014","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.ajog.2021.05.031_bib10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/ijgc-2020-001237","article-title":"Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America","volume":"30","author":"Maest\u00e1","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2021.05.031_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2017.04.010","article-title":"Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: a retrospective cohort study","volume":"146","author":"Kong","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib12","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ejca.2015.05.026","article-title":"Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases","volume":"51","author":"Bolze","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2021.05.031_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ajog.2021.05.031_bib15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1016\/j.ajog.2021.05.031_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/0272989X9701700203","article-title":"Primer on medical decision analysis: Part 3--Estimating probabilities and utilities","volume":"17","author":"Naglie","year":"1997","journal-title":"Med Decis Making"},{"key":"10.1016\/j.ajog.2021.05.031_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2015.09.012","article-title":"Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation","volume":"139","author":"Braga","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ygyno.2016.10.038","article-title":"Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?","volume":"144","author":"Miller","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib19","first-page":"211","article-title":"A\u00a0cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia","volume":"57","author":"Shah","year":"2012","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.ajog.2021.05.031_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2013.05.017","article-title":"Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia","volume":"130","author":"Maest\u00e1","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ygyno.2020.03.029","article-title":"Cost-effectiveness of second curettage for treatment of low-risk non-metastatic gestational trophoblastic neoplasia","volume":"157","author":"Batman","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib22","author":"Mitchell"},{"key":"10.1016\/j.ajog.2021.05.031_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2017.10.028","article-title":"Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience","volume":"148","author":"Maest\u00e1","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2003.08.028","article-title":"Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy","volume":"91","author":"Escobar","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1525-1438.2007.00999.x","article-title":"EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients","volume":"18","author":"Lu","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2021.05.031_bib27","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ejca.2012.09.015","article-title":"Comparing cisplatin-based combination chemotherapy with EMA\/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia","volume":"49","author":"Lybol","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2021.05.031_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2019.07.024","article-title":"When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): a national analysis on over 4,000 patients","volume":"155","author":"Balachandran","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/AOG.0b013e3181ee6e4d","article-title":"Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer","volume":"116","author":"Barnett","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.031_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2016.01.005","article-title":"The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy","volume":"140","author":"Gockley","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib34","doi-asserted-by":"crossref","first-page":"334.e1","DOI":"10.1016\/j.ajog.2016.04.019","article-title":"Effect of race\/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center","volume":"215","author":"Gockley","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.031_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.AOG.0000227754.12848.4e","article-title":"Low risk of relapse after achieving undetectable hCG levels in women with partial molar pregnancy","volume":"108","author":"Wolfberg","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.031_bib36","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.AOG.0000136099.21216.45","article-title":"Low risk of relapse after achieving undetectable hCG levels in women with complete molar pregnancy","volume":"104","author":"Wolfberg","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.031_bib37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study","volume":"29","author":"Osborne","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib38","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.1997.15.7.2636","article-title":"EMA\/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients","volume":"15","author":"Bower","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"10.1016\/j.ajog.2021.05.031_bib40","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.05.031_bib41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2005.01.015","article-title":"The impact of molar pregnancy on psychological symptomatology, sexual function, and quality of life","volume":"97","author":"Petersen","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ajog.2021.05.031_bib44","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/1471-0528.12241","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"120","author":"Husereau","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2021.05.031_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.12.008","article-title":"What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients","volume":"148","author":"Coyle","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.031_bib46","first-page":"588","article-title":"Outcome of pregnancies occurring within 1 year of hydatidiform mole","volume":"94","author":"Tuncer","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.031_bib47","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/humrep\/16.6.1274","article-title":"Subsequent pregnancy outcome in patients with spontaneous resolution of HCG after evacuation of hydatidiform mole: comparison between complete and partial mole","volume":"16","author":"Matsui","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2021.05.031_bib48","doi-asserted-by":"crossref","first-page":"372.e1","DOI":"10.1016\/j.ajog.2020.09.048","article-title":"Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression","volume":"224","author":"Lin","year":"2021","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821005998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821005998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:47Z","timestamp":1757590487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821005998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0002937821005998"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.05.031","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}